Ipsen, a global specialty-driven biotechnological group based in France, has announced the opening of its new R&D center, Ipsen Bioscience, in Cambridge Mass., a U.S. hub for biomedical research and innovation. Ipsen’s strategic decision to invest in the Ipsen Bioscience facility in Cambridge is an important element of the company’s open innovation strategy and its goal of broadening its partnerships with the American biotech, medical and scientific communities.
Ipsen Bioscience is developing highly differentiated peptide therapeutics that address unmet medical needs in endocrinology and oncology. This work is supported by Ipsen’s peptide and toxin experience, notable for the discovery of innovative solutions for debilitating diseases. Ipsen is one of a few companies to master the manufacture and control of targeted secretion inhibitors (TSIs), and are further exploring the potential of peptides to modulate intracellular protein-protein interactions.
Ipsen Biopharmaceuticals, the North American operations of Ipsen, has offices in Basking Ridge, N.J. and Toronto and is focused on the commercialization and the medical and clinical support of its key products in oncology, neurology and endocrinology.